Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022)

Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Restructuring Costs of $5.0 million in Q2 2022.

Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022) Analysis & Trends

Corbus Pharmaceuticals Holdings' Restructuring Costs history runs 1 years deep, the most recent figure standing at $5.0 million for Q2 2022.

In Q2 2022, Restructuring Costs changed N/A year-over-year to $5.0 million; the TTM figure through Jun 2023 stood at $5.0 million (changed N/A YoY), while the FY2022 annual figure was $5.0 million, changed N/A from the prior year.
Restructuring Costs was $5.0 million for Q2 2022 at Corbus Pharmaceuticals Holdings.
In the past five years, Restructuring Costs ranged from a high of $5.0 million in Q2 2022 to a low of $5.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Corbus Pharmaceuticals Holdings	133.67 Mn	105.86 Mn	-

Download Data

Date	Value
Jun 30, 2022	5.00 Mn